Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase

Jennifer Nielsen Kahn, Guillermo Garcia-Effron, Ming-Jo Hsu, Steven Park, Kieren A. Marr, David S. Perlin
Jennifer Nielsen Kahn
1Merck Research Laboratories, Rahway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillermo Garcia-Effron
2Public Health Research Institute, New Jersey Medical School—UMDNJ, Newark, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming-Jo Hsu
1Merck Research Laboratories, Rahway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Park
2Public Health Research Institute, New Jersey Medical School—UMDNJ, Newark, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kieren A. Marr
3Fred Hutchinson Cancer Research Center, Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David S. Perlin
2Public Health Research Institute, New Jersey Medical School—UMDNJ, Newark, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: perlin@phri.org
DOI: 10.1128/AAC.00067-07
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A Candida krusei strain from a patient with acute myelogenous leukemia that displayed reduced susceptibility to echinocandin drugs contained a heterozygous mutation, T2080K, in FKS1. The resulting Phe655→Cys substitution altered the sensitivity of glucan synthase to echinocandin drugs, consistent with a common mechanism for echinocandin resistance in Candida spp.

Clinical antifungal resistance in fungi has been best characterized with azole drugs and is associated with a variety of mechanisms including direct modification of the target enzyme, levels of the target enzyme, decreased drug accumulation due to efflux pump overexpression, or some combination of these mechanisms (15). Less is known about reduced echinocandin susceptibility (RES), but resistance in Candida spp. has been associated only with mutations in the Fks1p subunit of the target enzyme (1, 3)-β-d-glucan synthase (4-6, 10). Hakki et al. recently reported a case of invasive and oropharyngeal candidiasis caused by a Candida krusei isolate that developed RES after caspofungin (CFG) therapy. The preliminary evaluation did not reveal any modification of the FKS1 gene sequence in the isolate with reduced susceptibility (2). To determine if the RES phenotype in this strain could be due to a different mechanism, pre- and post-CFG treatment strains were further assessed for genetic and biochemical modifications of glucan synthase.

Echinocandin susceptibility testing with CFG, micafungin, and anidulafungin was performed in triplicate using the broth microdilution method of CLSI (formerly NCCLS) document M27-A2 (8) with modifications (10). C. krusei strains (2) Ck98 (pretreament) and Ck100 (posttreatment) were grown with vigorous shaking at 30°C to early-stationary phase in YPD broth (2% yeast extract, 4% Bacto peptone, 4% dextrose). Glucan synthase isolation and CFG titration were done as described previously (10). Inhibition curves and 50% inhibitory concentrations (IC50s) were determined using a sigmoidal response (variable-slope) curve and a two-site competition fitting algorithm with GraphPad Prism, version 4.0, software (Prism Software, Irvine, CA). Genomic DNA, obtained twice from each of five separate colonies, was extracted from cells grown overnight in YPD broth medium with the Q-Biogene (Irvine, CA) FastDNA kit. PCR amplification was performed on an iCycler thermocycler (Bio-Rad Laboratories, Hercules, CA). The FKS1 genes from both strains were PCR amplified using Sure-Pol DNA polymerase (Denville Scientific Inc., Metuchen, NJ). DNA sequencing of the 5.9-kb gene was performed with a CEQ dye terminator cycle sequencing Quick Start kit (Beckman Coulter, Fullerton, CA) according to the manufacturer's recommendations. Sequencing analyses were done with the CEQ 8000 genetic analysis system software (Beckman Coulter, Fullerton, CA) and with the BioEdit sequence alignment editor (Ibis Therapeutics, Carlsbad, CA).

The MICs of echinocandin drugs for strain Ck-100 were 16- to 32-fold higher than those for the susceptible pretreatment strain, Ck-98 (Table 1), as previously reported (2). Moreover, the CFG MIC for Ck-100 exceeded the maximum range of 1 μg/ml reported for several large collections of clinical isolates using the CLSI M27-A2 method (9, 11-14). The reduced microbiological susceptibility of Ck-100 to CFG was confirmed in glucan synthase enzyme assays. A standard monophasic inhibition curve was obtained for Ck-98, yielding an IC50 of 6.8 ng/ml (Fig. 1). In contrast, biphasic inhibition was obtained for the product-entrapped enzyme from strain Ck-100, with IC50s of 8.4 ng/ml and 3,942 ng/ml (Fig. 1). The presence of two distinct inflection points (two IC50s) suggested a possible heterozygous genotype, as has been observed previously with Candida albicans (5, 6, 10). DNA sequence analysis of the entire fks1 gene uncovered heterozygosity at a single nucleotide position, nucleotide T2080K, based on GenBank accession no. EF426563 (equivalent to nucleotide T2629 in C. albicans GenBank accession no. D88815). Both the wild-type and G-substituted fks1 genes were observed in each of the five PCR products analyzed from strain Ck-100 (Fig. 2C and D). This nucleotide heterozygosity results in deduced amino acid heterogeneity—the wild type TTC codon encoding F and the modified TGC codon encoding C (Fig. 2B). None of the PCR products amplified from Ck-98 genomic DNA shared this nucleotide substitution (Fig. 2A). Failure to detect mutations in FKS1 previously (2) likely results from the analysis of only one cloned allele. Since C. krusei is a diploid or aneuploid organism (3, 17), the cloning of one allele or another in a bacterial plasmid is a matter of chance.

The amino acid substitution at this position in C. krusei Fks1p is located in the highly conserved “hot spot 1” region of the protein (Fig. 2B) (10). Heterozygous amino acid changes in this region are associated with CFG resistance in both Saccharomyces cerevisiae laboratory strains and C. albicans clinical isolates (5, 6, 10). However, the only other reported C. krusei clinical isolate with RES had a predicted R1361G substitution in “hot spot 2” of Fks1p (10). Thus, clinical isolate Ck-100 is the first echinocandin-resistant C. krusei strain to be associated with a mutation in “hot spot 1.”

The results obtained in this work highlight the need to monitor C. krusei infections treated with echinocandin drugs for the development of resistance. This is especially important because mortality from C. krusei, like that from other Candida spp., remains high (7, 16, 18) and treatment options are limited due to intrinsic resistance to fluconazole (1).

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

CFG inhibition profiles for product-entrapped glucan synthases. Enzyme complexes were obtained from pretreatment (Ck-98) (squares) and posttreatment (Ck-100) (triangles) C. krusei strains. Inhibition curves and IC50s (in nanograms per milliliter) were obtained using a sigmoidal response (variable-slope) curve (strain Ck-98) and a two-site competition fitting algorithm (strain Ck-100).

FIG. 2.
  • Open in new tab
  • Download powerpoint
FIG. 2.

DNA sequencing chromatograms and amino acid sequence alignment for C. krusei strains. (A) C. krusei strain Ck-98 Fks1p HS1 (forward primer). (B) Sequence alignments of the Fks1p HS1 region (boxed) in different fungal species. Line 1, C. krusei wild-type allele (GenBank accession no. AAY40291.1); line 2, C. krusei Ck-100 mutated allele; line 3, Yarrowia lipolytica (XP_504213); line 4, Aspergillus fumigatus (AAB58492); line 5, Coccidioides immitis (EAS36399); line 6, C. albicans (XP_721429); line 7, Debaryomyces hansenii (XP 457762); line 8, Kluyveromyces lactis (CAH02189); line 9, Schizosaccharomyces pombe (NP_588501); line 10, Saccharomyces cerevisae (AAZ22447). (C and D) C. krusei strain Ck-100 Fks1p HS1. (C) Forward primer; (D) reverse primer.

View this table:
  • View inline
  • View popup
TABLE 1.

Echinocandin susceptibilities of C. krusei clinical strains

FOOTNOTES

    • Received 16 January 2007.
    • Returned for modification 28 January 2007.
    • Accepted 12 February 2007.
  • Copyright © 2007 American Society for Microbiology

REFERENCES

  1. 1.↵
    Charlier, C., E. Hart, A. Lefort, P. Ribaud, F. Dromer, D. W. Denning, and O. Lortholary. 2006. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother.57:384-410.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Hakki, M., J. F. Staab, and K. A. Marr. 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother.50:2522-2524.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Jacobsen, M. D., N. A. Gow, M. C. Maiden, D. J. Shaw, and F. C. Odds. 22 Nov. 2006. Strain typing and determination of population structure of Candida krusei determined by multilocus sequence typing. J. Clin. Microbiol. doi:10.1128/JCM.01549-06.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Katiyar, S., M. Pfaller, and T. Edlind. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother.50:2892-2894.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Laverdiere, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother.57:705-708.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Miller, C. D., B. W. Lomaestro, S. Park, and D. S. Perlin. 2006. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy26:877-880.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother.49:3640-3645.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd ed. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
  9. 9.↵
    Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother.47:3149-3154.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother.49:3264-3273.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol.44:3533-3538.
    OpenUrlAbstract/FREE Full Text
  12. 12.
    Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2005. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol.43:5425-5427.
    OpenUrlAbstract/FREE Full Text
  13. 13.
    Pfaller, M. A., D. J. Diekema, S. A. Messer, R. J. Hollis, and R. N. Jones. 2003. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother.47:1068-1071.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    Roling, E. E., M. E. Klepser, A. Wasson, R. E. Lewis, E. J. Ernst, and M. A. Pfaller. 2002. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn. Microbiol. Infect. Dis.43:13-17.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    Sanglard, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis.2:73-85.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    Weinberger, M., L. Leibovici, S. Perez, Z. Samra, I. Ostfeld, I. Levi, E. Bash, D. Turner, A. Goldschmied-Reouven, G. Regev-Yochay, S. D. Pitlik, and N. Keller. 2005. Characteristics of candidaemia with Candida albicans compared with non-albicans Candida species and predictors of mortality. J. Hosp. Infect.61:146-154.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    Whelan, W. L., and K. J. Kwon-Chung. 1988. Auxotrophic heterozygosities and the ploidy of Candida parapsilosis and Candida krusei. J. Med. Vet. Mycol.26:163-171.
    OpenUrlPubMed
  18. 18.↵
    Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis.39:309-317.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase
Jennifer Nielsen Kahn, Guillermo Garcia-Effron, Ming-Jo Hsu, Steven Park, Kieren A. Marr, David S. Perlin
Antimicrobial Agents and Chemotherapy Apr 2007, 51 (5) 1876-1878; DOI: 10.1128/AAC.00067-07

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase
Jennifer Nielsen Kahn, Guillermo Garcia-Effron, Ming-Jo Hsu, Steven Park, Kieren A. Marr, David S. Perlin
Antimicrobial Agents and Chemotherapy Apr 2007, 51 (5) 1876-1878; DOI: 10.1128/AAC.00067-07
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

antifungal agents
Candida
Glucosyltransferases
lipoproteins
Peptides, Cyclic

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596